Ticker

OTLK

Outlook Therapeutics, Inc.

15 catalysts on file

OTLK

Outlook Therapeutics, Inc.

CRL AI-extracted

ONS-5010/LYTENAVA™ (bevacizumab-vikg)

retinal diseases

234d ago Dec 30, 2025

SEC 8-K verified 2mo ago

Countdown card →

OTLK

Outlook Therapeutics, Inc.

CRL Confirmed

ONS-5010/LYTENAVA

neovascular age-related macular degeneration (nAMD)

234d ago Dec 30, 2025

SEC 8-K verified 2mo ago

Countdown card →

OTLK

Outlook Therapeutics, Inc.

CRL Confirmed

ONS-5010

wet AMD

234d ago Dec 30, 2025

SEC 8-K verified 2mo ago

Countdown card →

OTLK

Outlook Therapeutics, Inc.

CRL Confirmed

LYTENAVA

neovascular age-related macular degeneration

234d ago Dec 30, 2025

SEC 8-K verified 2mo ago

Countdown card →

OTLK

Outlook Therapeutics, Inc.

Catalyst AI-extracted

ONS-5010

wet age-related macular degeneration (wet AMD)

185d ago Feb 17, 2026

SEC 8-K verified 2mo ago

Countdown card →

OTLK

Outlook Therapeutics, Inc.

PDUFA AI-extracted

ONS-5010/LYTENAVA

neovascular age-related macular degeneration (nAMD)

112d ago ~ May 1, 2026

SEC 8-K verified 2mo ago

Countdown card →

OTLK

Outlook Therapeutics, Inc.

Catalyst AI-extracted

LYTENAVA

neovascular age-related macular degeneration

52d ago Jun 30, 2026

SEC 8-K verified 2mo ago

Countdown card →

OTLK

Outlook Therapeutics, Inc.

PDUFA Confirmed

ONS-5010/LYTENAVA™ (bevacizumab-vikg)

wet AMD

23d ago Jul 29, 2026

SEC 8-K verified 2mo ago

Countdown card →

OTLK

Outlook Therapeutics, Inc.

PDUFA Confirmed

ONS-5010

bevacizumab-vikg

23d ago Jul 29, 2026

SEC 8-K verified 2mo ago

Countdown card →

OTLK

Outlook Therapeutics, Inc.

AdCom AI-extracted

ONS-5010/LYTENAVA™ (bevacizumab-vikg)

retinal diseases

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →

OTLK

Outlook Therapeutics, Inc.

Approval AI-extracted

ONS-5010/LYTENAVA

neovascular age-related macular degeneration (nAMD)

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →

OTLK

Outlook Therapeutics, Inc.

AdCom AI-extracted

ONS-5010/LYTENAVA

wet age-related macular degeneration

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →

OTLK

Outlook Therapeutics, Inc.

Phase 3 Confirmed

ONS-5010/LYTENAVA

wet age-related macular degeneration

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →

OTLK

Outlook Therapeutics, Inc.

AdCom AI-extracted

ONS-5010

wet AMD

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →

OTLK

Outlook Therapeutics, Inc.

Approval AI-extracted

LYTENAVA

neovascular age-related macular degeneration

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →